LENSAR Q3 2021 revenue $8.3M (+16% YoY), net loss widens to $6.2M

LENSAR, Inc.

2022-Q3 EPS reported -$1.69 revenue$23,237,000

Revenue $8.3M, up 16% YoY; procedure volumes grew 23% over Q3 2020.
Net loss of $6.2M ($0.65 loss per share) vs. $4.8M loss ($0.64 per share) in Q3 2020.
R&D spending surged 59% to $3.2M, driven by development of ALLY Adaptive Cataract Treatment System.
Cash and equivalents $32.3M; cash utilization $2.2M in the quarter.
Adjusted EBITDA was ($3.9M) compared to ($0.4M) in Q3 2020, reflecting higher R&D and SG&A.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.